Amgen’s Parsabiv approved in Europe for sHPT treatment in adults with CKD
Parsabiv is a calcimimetic agent where a healthcare provider can administer it intravenously three times per week at the end of a hemodialysis session. A calcimimetic is a
Boehringer Ingelheim has received Japan’s Ministry of Health, Labour and Welfare (MHLW) approval for Jascayd (nerandomilast) to treat adults with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF).
The Prospective Randomized Evaluation of CelecoxibIntegrated Safety vs. Ibuprofen Or Naproxen (Precision) demonstrated that Celebrex has similar cardiovascular risk as compared to prescription doses Of Ibuprofen and Naproxen. The findings contradict some of the researchers’ belief